BIOTECHNOLOGY

New drug technologies for today’s diseases

INVESTMENT CASE
Remove Section

BIOTECHNOLOGY

 

Remove Section

The investment universe focuses on tomorrow's new generation of drugs that might revolutionize the future of biotechnology. Such technologies include RNA-based drugs, cell and gene therapies, in addition to a new generation of vaccines.

Medical innovations will allow for more personalized treatment and better diagnosis. Such innovations are further supported by authorities such as the FDA that encourages the approval of this new generation of drugs by recruiting specialized teams and establishing specific guidelines.

Research and development, through partnerships or M&A, will continue to play a strategic role for companies seeking innovation.

 

 FACTSHEET

 PRESENTATION

TERMSHEET

                                                                                                                                

KIDs (Biotechnology)      

PRICE
158.85 Aug. 5, 2020
Remove Section

WHAT IS IT ABOUT?
Remove Section

BIOTECHNOLOGY
NEW TECHNOLOGIES FOR HEALTH

 

 

  • The term has appeared for the first time with the discovery of DNA.
     
  • Modern biotechnology involves the use of live organisms or their products (bacteria or enzymes) to manufacture drugs.
     
  • Biotechnology products have wider applications than classic pharma.
  • A completely different business model than pharma.
     
  • Today lines are blurred between pure biotech and pharmaceutical companies as these industries are partially consolidating.

 

SOLUTION TO A GLOBAL SOCIAL ISSUE

THE HOPE OFFERING
 

 

WHAT IS HAPPENING NOW?

 

Remove Section

UPCOMING CATALYSTS

 

 

Remove Section

2017 IS EXPECTED TO BE A RECORD YEAR FOR FDA APPROVALS

 

Food and Drug Administration - the first level of decision-making before commercialization: 

 

  • Consistent legal and political framework across states,
  • FDA has the most demanding approval standards in the world.

 

The FDA does not make decision on drug reimbursement:

 

  • Insurance companies have the right to take this decision individually.
  • Biotech companies start reimbursement discussions at the earliest stages of research.

 

 

A record year for FDA approvals in 2015, followed by an unprecedented low number in 2016 as fewer applications were submitted and complete response letters (CRLs) were sent due to manufacturing practice deficiencies (GMP), again followed by a new record year in 2017 as:

 

  • Many important drugs in the last stages of development were (and are still) waiting for an approval.
     
  • The 21st Century Cure Bill gets new drugs and devices approved faster.
     
  • A streamlined FDA → Accelerate the approval process for new drugs (including generics).

PERCENTAGE OF PEOPLE BY TYPE OF
HEALTH INSURANCE COVERAGE IN US

 

 Source: Census Bureau's March 2014, March 2015, and March 2016
Current Population Survey (CPS: Annual Social and Economic Supplements)

 

 

NUMBER OF DRUGS APPROVED BY FDA

 

 

Source: AtonRâ Partners, FDA

Remove Section

PERSONALIZED MEDICINE: 
THE FUTURE OF MEDICINE?

 

  • Treatments targeted to the needs of individual patients.
     
  • Technological breakthroughs and computer power are accelerating the field.
     
  • Strong government support.

 

 

 

Remove Section

CHANGING NUTRITION HABITS:

WHAT ARE THE OUTCOMES?

 

Remove Section

Obesity is one of the biggest health concerns. Obesity levels are rising. Across the United States, more than one in three adults and one in six children are obese (13% of worldwide obese population comes from the U.S.).

The two countries showing the highest growth in obesity level are China and India (15% of the worldwide obese population) leading to:

  • Cardiovascular diseases
  • Diabetes
  • Musculoskeletal disorders
  • Cancers

 

Remove Section

EMERGING MARKETS: 
A REAL OPPORTUNITY FOR BIOTECH

 

  • Huge populations
     
  • Increasing prosperity and standards of living
    (growing middle class)
     
  • Aging population


Emerging markets will lead the diabetics industry growth. Global executives are expecting 30% of their biopharmaceutical sales to come from emerging markets by 2018.

2017 IS EXPECTED TO BE

A VERY STRONG YEAR IN M&A

 

 

 

PERSPECTIVES
Remove Section

GLOBAL PERSPECTIVES IN THE LONG-RUN

 

Global biotechnology market expected
to grow by 8% CAGR through 2020

 

 

Remove Section
Source: MarketLine Industry Profile

 

Remove Section

Top 10 therapeutics areas by 2022
MARKET SHARE & SALES GROWTH 

 

 

Remove Section

Source: EvaluatePharma 2016

 

THERAPEUTIC AREAS
Remove Section

GLOBAL MORTALITY CASES IN 2015 

(by number of cases)

Remove Section

 

 

Source: AtonRâ Partners, The Lancet

 

 

 

Remove Section

NEW CHALLENGES FOR A NEW WORLD
 

 

Oncology cases have increased by 17% worldwide during the last 10 years due to aging population (probability increases with age).
 
Neurological Diseases are affecting more and more people (+35.2% growth from 2005) due to: aging population, obesity, smoking and genetic predisposition.
 
Infection cases have decreased by 10% during the last 10 years led primarily by decreases in HIV/AIDS and tuberculosis cases.

Diabetes and chronic kidney diseases increased by 30% from 2005 worldwide due to: obesity, high blood pressure, smoking, environmental, inactivity.

Cheaper gene sequencing triggers the development of personalized medicine notably in oncology.

IMPACT OF DIABETES

 

 

 

Remove Section

RARE DISEASES AFFECT
 

Remove Section

 

Rare diseases are more and more attractive due to governmental support and higher profit margins.

      

 

Terms of use and legal information

Please read this notice carefully

Term of Use

By accessing this website ("Site") and any of its pages you expressly agree that you have read, understood and agree to be bound by the terms and conditions and the legal information contained herein. If you do not agree to the terms and conditions below, you should exit the Site now.

Access to the information contained on this Site may be subject to legal and regulatory restrictions applicable to user (by reason of user’s place of residence or domicile, nationality, or for any other reason). Persons concerned by such prohibitions should not enter the Site.

No offer, solicitation or recommendation

The contents of this Site are provided for information purposes only. Nothing contained on this Site constitutes a solicitation, an offer or a recommendation to purchase or sell any product and/or may be construed as an offer, an invitation or solicitation to enter into any specific transaction or strategy. None of the products mentioned on this Site are available and term sheet shall not be distributed to any person or entity in any jurisdiction or country where such distribution or use would be contrary to any applicable law or regulation.

The collective investment scheme (hereinafter referred to as the "Fund") referred to on this Site is registered only in Luxembourg.

US restrictions

The products mentioned on the Site may not be offered, sold, assigned, or delivered, directly or indirectly at any time by any “US person”. In particular, the Fund mentioned on the Site has not been nor will be registered under the Securities Act of 1933 in the USA.

No warranty, no investment advice

Although AtonRâ Partners believes that the information is reliable when posted on the Site, it makes no representation or guarantee that it is accurate or complete.

The information and opinions contained on the Site are subject to change without notice.

Limitation of liability

AtonRâ Partners shall not be responsible or liable for any loss or damage of any nature whatsoever (including direct, indirect, incidental or consequential) arising out of or in connection with the access to or the use of, or any inability to access or to use any information or data on this Site, including without limitation in the event of negligence.

Copyright

Unless expressly stated otherwise, all information available on this Site is protected by copyright, with all rights reserved. The elements may be used freely for navigation purposes only and must expressly mention AtonRâ Partners in the event of reproduction, in whole or in part, of such elements in any form whatsoever, including in written or electronic form. No part of this Site may be distributed or transmitted without the express consent of AtonRâ Partners. Links to the Site or use of the content for advertising or commercial purposes is subject to the prior written consent of AtonRâ Partners.

Data protection

AtonRâ Partners places great importance on data protection and makes every effort to safeguard the privacy of information. However, the Internet, like other electronic information and communication systems, cannot guarantee absolute security.

Governing law and jurisdiction

Use of this Site is subject to the laws of Switzerland without reference to any conflict of law principles. The courts of Geneva, Switzerland, shall have exclusive jurisdiction over any claims or disputes arising out of or in connection with the Site and its use.

By clicking on 'I AGREE', I acknowledge having read the terms of use and legal information and agree with the above statements.